title: Simultaneous novel BCR-ABL gene mutation and increased expression of BCR-ABL mRNA caused clinical resistance to STI571 in double-Ph-positive acute biphenotypic leukemia.
authors.forename: Mitsuharu
authors.initials: M
authors.lastname: Inami
authors.forename: Koiti
authors.initials: K
authors.lastname: Inokuchi
authors.forename: Kazutaka
authors.initials: K
authors.lastname: Nakayama
authors.forename: Hideto
authors.initials: H
authors.lastname: Tamura
authors.forename: Takashi
authors.initials: T
authors.lastname: Shimada
authors.forename: Kazuo
authors.initials: K
authors.lastname: Dan
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001549:Benzamides; D019008:Drug Resistance, Neoplasm; D015973:Gene Expression Regulation, Leukemic; D016313:Genes, abl / Q000235:genetics*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D010677:Philadelphia Chromosome; D010879:Piperazines / Q000008:administration & dosage*; D011743:Pyrimidines / Q000008:administration & dosage*; D012333:RNA, Messenger / Q000235:genetics
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D012333:RNA, Messenger; D000068877:Imatinib Mesylate